DDX29 Activators
DDX29 Activators encompass a range of chemical compounds that indirectly augment the functional activity of DDX29, a gene encoding an RNA helicase involved in RNA metabolism and processing. Compounds like Forskolin, A23187, and Thapsigargin work by modulating intracellular levels of cAMP and calcium, respectively. Forskolin, through cAMP elevation, and A23187, via increased calcium levels, can potentially enhance DDX29's RNA helicase activity by activating PKA and calcium-dependent signaling pathways that intersect with RNA processing pathways. Thapsigargin, by raising intracellular calcium, similarly could influence pathways that enhance DDX29's role in RNA metabolism.
Furthermore, kinase inhibitors such as LY 294002, U0126, Genistein, and (-)-Epigallocatechin Gallate indirectly influence DDX29's activity by modulating various signaling pathways. LY 294002 and U0126, by inhibiting the PI3K/AKT and MEK1/2 pathways, respectively, can shift the cellular signaling balance, potentially enhancing DDX29's function in RNA processing. Genistein and (-)-Epigallocatechin Gallate, by inhibiting competitive tyrosine kinase and other kinases, might reduce negative regulation on pathways in which DDX29 is involved, promoting its functional activity. Additionally, compounds like Staurosporine and PMA, through their roles as a broad-spectrum protein kinase inhibitor and a PKC activator, respectively, might modulate signaling pathways that intersect with DDX29's RNA helicase function. Rapamycin, an mTOR inhibitor, could also play a role in enhancing DDX29 activity by impacting mTOR signaling pathways, which have potential intersections with RNA processing pathways. These activators, through their targeted effects on cellular signaling, facilitate the enhancement of DDX29's functions in RNA metabolism.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular cAMP levels, which could indirectly activate DDX29 by stimulating cAMP-dependent protein kinase A (PKA). PKA may influence pathways that modulate the RNA helicase activity of DDX29, enhancing its role in RNA processing. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002, a PI3K inhibitor, can indirectly enhance DDX29 activity by modulating PI3K/AKT pathway signaling, potentially affecting pathways that intersect with DDX29's function in RNA metabolism. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580, a p38 MAPK inhibitor, can shift signaling towards pathways where DDX29 is involved, particularly in stress response and RNA processing, indirectly enhancing its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
D-erythro-Sphingosine-1-phosphate impacts lipid signaling pathways that could intersect with pathways involving DDX29, potentially enhancing its role in RNA metabolism and helicase activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin raises intracellular calcium levels, potentially activating pathways that intersect with those where DDX29 functions, enhancing its RNA helicase activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, as a tyrosine kinase inhibitor, might indirectly enhance DDX29 activity by reducing competitive signaling, potentially allowing DDX29-related RNA processing pathways to be more active. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
(-)-Epigallocatechin Gallate, a kinase inhibitor, might promote DDX29 activation by inhibiting kinases that negatively regulate pathways involving DDX29, particularly in RNA metabolism. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a broad-spectrum protein kinase inhibitor, could indirectly activate DDX29 pathways by lifting inhibition on pathways that are relevant to DDX29's RNA helicase function. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA, as a PKC activator, could enhance DDX29 activity by modulating PKC-dependent pathways that interact with RNA processing pathways where DDX29 is involved. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 could enhance DDX29's activity by increasing intracellular calcium levels, activating calcium-dependent signaling pathways that intersect with DDX29's function in RNA metabolism. | ||||||